Savaysa Generic Name & Formulations
Edoxaban 15mg, 30mg, 60mg; tabs.
Factor Xa inhibitor.
Tabs 15mg—30; 30mg, 60mg—30, 90, 500
To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5–10 days of initial therapy with parenteral anticoagulant.
Limitations of Use
Not for use in NVAF patients with CrCl >95mL/min.
Savaysa Dosage and Administration
Assess CrCl prior to initiation. NVAF: CrCl >50mL/min: 60mg once daily; CrCl 15–50mL/min: 30mg once daily. DVT/PE: CrCl >50mL/min: 60mg once daily following initial parenteral anticoagulant; CrCl 15–50mL/min, body wt. ≤60kg, or concomitant P-gp inhibitors: 30mg once daily. Transition to or from Savaysa: see full labeling.
Active pathological bleeding.
Savaysa Boxed Warnings
Reduced efficacy in nonvalvular atrial fibrillation (NVAF) patients with CrCl >95mL/min. Premature discontinuation increases the risk of ischemic events. Spinal/epidural hematoma.
Reduced efficacy in NVAF patients with CrCl >95mL/min; use another anticoagulant. Premature discontinuation increases risk of ischemic events; if discontinued for reason other than bleeding or therapy completion, consider coverage with another anticoagulant. Increased risk of spinal/epidural hematoma in anticoagulated patients receiving neuraxial anesthesia or undergoing spinal puncture (eg, use of indwelling epidural catheters); monitor for neurological impairment. Increased risk of bleeding; monitor for signs/symptoms of blood loss; discontinue if active pathological hemorrhage occurs. Patients with mechanical heart valves, moderate to severe mitral stenosis, triple(+) antiphospholipid syndrome (increased risk of thrombosis): not recommended. Discontinue at least 24hrs before surgery. Renal impairment (CrCl <15mL/min), moderate or severe hepatic impairment (Child-Pugh B and C): not recommended. Labor & delivery. Pregnancy. Females of reproductive potential. Abnormal uterine bleeding. Nursing mothers: not recommended.
Increased risk of bleeding with concomitant aspirin, other antiplatelets or antithrombotic agents, fibrinolytic therapy, chronic NSAIDs, SSRIs, and SNRIs; monitor. Concomitant other anticoagulants in long term therapy: not recommended. Monitor for bleeding in chronic treatment with low dose aspirin and/or NSAIDs. Avoid concomitant P-gp inducers (eg, rifampin).
Savaysa Adverse Reactions
Bleeding (may be serious or fatal), anemia, rash, abnormal LFTs.
Savaysa Clinical Trials
Savaysa Patient Counseling